ReviewJournal of medical case reports2018
Chordoma: a case series and review of the literature.
Review in Journal of medical case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Ultrastructural pathological features and clinical significance of recurrent chordoma.Journal of bone oncology · 2026Article
- Sacral Chordoma: Multimodality Imaging and Radiologic-Pathologic Correlation of a Rare Malignant Sacral Tumor.Cureus · 2026Article
- Loss of CD90 alters EMT-associated features and drug sensitivity in U-CH1 chordoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma.Global spine journal · 2025Article
- Clival chordomas and chondrosarcomas in Denmark-Outcomes in 33 patients following the national centralization of treatment in 2010.Acta neurochirurgica · 2024Article
- Dysregulation of noncoding RNA in chordoma; implications in identifying potential targets for novel therapeutic approaches.Molecular biology reports · 2024Review
- Long-term outcomes of high dose carbon-ion radiation therapy for unresectable upper cervical (C1-2) chordoma.Head & neck · 2022Article
- Cervical Paraspinal Chordoma: A Literature Review with a Novel Case Report.Journal of clinical medicine · 2022Article
- Systematic Review Comparing Open versus Endoscopic Surgery in Clival Chordomas and a 10-Year Single-Center Experience.Journal of neurological surgery. Part B, Skull base · 2022Article
- Selective Dysarthria Due to Clival Chordoma.Neurology. Clinical practice · 2021Article
- Multiple malignant tumors in a patient with familial chordoma, a case report.BMC medical genomics · 2021Article
- Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients.World journal of surgical oncology · 2021Article
- Intraoperative Magnetic Resonance Imaging Assisted Endoscopic Endonasal Resection of Clival Chordomas.Frontiers in oncology · 2021Article
- Sacral and thoracic chordoma with pulmonary metastases: A case report and review of the literature.Molecular and clinical oncology · 2021Article
- Recurrent Sacral Chordoma: A Case Report.JNMA; journal of the Nepal Medical Association · 2020Article
- Comprehensive Review of Cranial Chordomas Using National Databases in the USA.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2019Review
- Chordoma: Site-Wise Predilections and Pathological Tenets.Journal of the West African College of SurgeonsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChordoma is a rare malignant tumor of the skull base and axial skeleton, with an incidence of less than 0.1/100,000 per year. Patients with advanced chordoma have a poor prognosis due to locoregional recurrence with infiltration and destruction of surrounding bone and soft tissue. Cytotoxic chemotherapy or other systemic therapies have not been proven to be effective for these diseases. Therefore, several molecularly targeted therapies have been proposed as potentially beneficial, including tyrosine kinase inhibitors such as imatinib, sorafenib, lapatinib, and others. CASE PRESENTATION: We present three cases of advanced chordoma treated with molecular targeted therapies: a 52-year-old Caucasian man, a 72-year-old Caucasian woman, and a 38-year-old Caucasian woman.
conclusionsChordoma has few systemic treatment options and they have limited benefit. Randomized trials with large patient numbers are unfeasible in this rare disease. Targeted therapy might be a reasonable alternative treatment for chordoma. Still, new treatment strategies are needed for this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.